Status:
COMPLETED
Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen
Lead Sponsor:
Anders Kvanta
Conditions:
Central Retinal Vein Occlusion
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Comparing ranibizumab and aflibercept in a treat and extend algorithm evaluating the number of needed injections over a 18 month period in patients with newly diagnosed CRVO.
Detailed Description
Forty patients diagnosed with a new central retinal vein occlusion (CRVO) of a maximum duration of 6 months will be recruited to the study. Patients will be randomized 1:1 to treatment with aflibercep...
Eligibility Criteria
Inclusion
- CRVO - naive patients, disease duration maximum 12 months, Best corrected visual acuity : 23-73 letters (20/40 - 20/320), Macular edema \> 300 μm (Cirrus)
Exclusion
- Neovascular Glaucoma Any previous treatment for CRVO. Intraocular surgery during the previous 3 months. Vascular retinopathy of other causes. Glaucoma with uncontrolled IOP (intra ocular pressure) Myocardial infarction or stroke during the last 3 months.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT02274259
Start Date
October 1 2014
End Date
December 1 2016
Last Update
December 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St Eriks Eye Hospital
Stockholm, Sweden, 11282